Last reviewed 2026-04-22 · How we verify

Course B1 +Vin

Course B1 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents in Course B1 to disrupt microtubule formation and induce apoptosis in cancer cells.

Course B1 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents in Course B1 to disrupt microtubule formation and induce apoptosis in cancer cells. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric lymphomas and other hematologic malignancies.

At a glance

Mechanism of action

This is a multi-agent chemotherapy regimen used in pediatric cancer treatment. Vincristine is a vinca alkaloid that binds to tubulin and prevents microtubule assembly, leading to cell cycle arrest and death. Course B1 typically refers to a standardized chemotherapy block in pediatric protocols (such as those for acute lymphoblastic leukemia), combining multiple cytotoxic agents to maximize tumor cell kill while managing resistance.

Approved indications

• Pediatric acute lymphoblastic leukemia (ALL)
• Pediatric lymphomas and other hematologic malignancies

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Peripheral neuropathy
• Mucositis
• Nausea and vomiting
• Alopecia

Key clinical trials

• CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Course B1 +Vin CI brief — competitive landscape report
• Course B1 +Vin updates RSS · CI watch RSS
• Children's Cancer Group, China portfolio CI